Search for: "Abbott Products Inc"
Results 441 - 460
of 664
Sort by Relevance
|
Sort by Date
20 Dec 2010, 8:05 pm
On Dec.7, 2010, the Department announced settlements totaling $421.1 million involving similar allegations against three other manufacturers: Abbott Laboratories Inc., B. [read post]
20 Dec 2010, 2:34 pm
December has been a significant month in terms of False Claims Act recoveries from pharmaceutical companies.Three drug makers - Abbott Laboratories Inc., Roxane Laboratories Inc. and B. [read post]
15 Dec 2010, 2:17 am
General Coming soon: International Classification of traditional medicine by WHO (Spicy IP) Teva Pharma uses online game to promote generic substitution (Patent Baristas) Australia: APO: Success of phase 3 trials ‘obvious’ in view of phase 1 and 2: Genentec, Inc (Patentology) Brazil: Government support to impel Brazil generic market (GenericsWeb) EU: EPO Enlarged Board of Appeal decides Broccoli (G2/07) and Tomatoes (G1/08) – essentially biological breeding processes not… [read post]
13 Dec 2010, 1:51 pm
Department of Justice announced that it has reached a settlement agreement with the pharmaceutical companies Abbott Laboratories Inc., B. [read post]
9 Dec 2010, 4:40 am
On December 8, the Department of Justice announced a settlement of off-label promotion allegations with Kos Pharmaceuticals, Inc. [read post]
9 Dec 2010, 3:53 am
Braun Medical Inc., and Roxane Laboratories Inc. [read post]
9 Dec 2010, 2:49 am
Braun Medical Inc., and Roxane Laboratories Inc. [read post]
8 Dec 2010, 6:07 pm
The medications include Abbott Laboratories Inc's Lupron, AstraZeneca's Zoladex and Sanofi-Aventis SA's Eligard.According to the FDA, the drugs, known as gonadotropin-releasing hormone (GnRH) agonists, are used to suppress the production of testosterone, a hormone that helps fuel prostate cancer growth. [read post]
8 Dec 2010, 2:20 am
Allergan, Inc (Docket Report) Products Enbrel (Etanercept) – Israel: Patent status in question, in need of legislative fix (America-Israel Patent Law) Fabrazyme (Alpha-galactosidase) – US: Statements by KEI and others on NIH rejection of Fabrazyme march-in request (KEI) Intuniv (Guanfacine) – US: Impax confirms patent challenge relating to Intuniv (GenericsWeb) Lovenox (Enoxaparin) – US: Momenta sues Teva over claims relating to ways of manufacturing and… [read post]
7 Dec 2010, 2:43 am
According to DOJ’s press release: Abbott Laboratories Inc., B. [read post]
6 Dec 2010, 2:36 am
Production Control Services, Inc. [read post]
3 Dec 2010, 5:11 am
Filed November 22, 2010, by Abbott Diabetes Care Inc. (3) 90/011,352 (electronically filed) - U.S. [read post]
3 Dec 2010, 5:11 am
Filed November 22, 2010, by Abbott Diabetes Care Inc. (3) 90/011,352 (electronically filed) - U.S. [read post]
24 Nov 2010, 8:22 am
Filed November 19, 2010 by Abbott Diabetes Care Inc. (15) 90/011,346 (electronically filed) - U.S. [read post]
24 Nov 2010, 8:22 am
Filed November 19, 2010 by Abbott Diabetes Care Inc. (15) 90/011,346 (electronically filed) - U.S. [read post]
23 Nov 2010, 9:54 pm
Noonan -- The Federal Trade Commission is nothing if not persistent in trying to eliminate "reverse payment" settlements in ANDA litigation, even going so far as to "forum shop" to do so, according to a brief by appellees Unimed Pharmaceuticals LLC, Abbott Products, Inc., and Watson Pharmaceuticals, Inc. [read post]
11 Nov 2010, 5:31 am
TiVo, Inc. v. [read post]
11 Nov 2010, 5:31 am
TiVo, Inc. v. [read post]
4 Nov 2010, 10:59 am
Apotex, Inc. [read post]
3 Nov 2010, 1:21 am
No – discussion of patent-eligibility standards for genes (Patent Baristas) US: Appellees file reply brief in Therasense v Becton Dickinson (Patent Docs) US: Another Capitol Hill missive objects to the inclusion of patent settlement provisions in FY 2011 Appropriations Bill (FDA Law Blog) US: REMS and 180-day exclusivity forfeiture – some interesting disclosures to the SEC (FDA Law Blog) Products Botox (Botulinum) – EU: General Court upholds opposition to BOTUMAX Community… [read post]
